The Chinese ST-Segment Elevation Myocardial Infarction Primary Percutaneous Coronary Intervention Registry
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI)
- Sponsor
- Renmin Hospital of Wuhan University
- Enrollment
- 5594
- Locations
- 1
- Primary Endpoint
- death
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to develop a risk score to predict the risks of in-hospital major adverse cardiac events in ST-segment elevation myocardial infarction patients treated by primary percutaneous coronary intervention.
Detailed Description
The CSPR trial is an observational clinical trial to derive and validate a readily useable risk score to identify patients at high risk of in-hospital major adverse cardiac events in 5594 patients presenting with a ST-segment elevation myocardial infarction and treated by primary percutaneous coronary intervention.
Investigators
Eligibility Criteria
Inclusion Criteria
- •ST-segment elevation myocardial infarction was defined according to the universal definition of myocardial infarction
- •STEMI treated by pPCI
Exclusion Criteria
- •Patient with heart failure in admission
- •STEMI with symptom-onset-to-balloon time\>24h
- •pPCI was not successful or only underwent coronary angiography
- •Killip class ≥II in admission
Outcomes
Primary Outcomes
death
Time Frame: in-hospital outcome, until discharge
according to the universal definition
in-hospital acute de novo heart failure
Time Frame: in-hospital outcome, until discharge
Killip class ≥II
cardiogenic shock
Time Frame: in-hospital outcome, until discharge
according to the universal definition